RxDoctor Payments Data

Mehul Thakkar, MD

Internal Medicine · Tarzana, CANPI 1801996640

Payments from drug & device makers

$1,866in general payments, 2019–2025

Across 95 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$492
  • AstraZeneca$331
  • Otsuka America Pharmaceutical, Inc.$166
  • Daiichi Sankyo Inc.$130
  • Merck$125
  • Genentech, Inc.$89
  • plus $533 from 15 others

What the payments were for

  • Food & beverage$1,82698%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,866 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$110,988
Medicare patients
363
Services billed
3,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$64,311
JardianceEmpagliflozin58$53,113
MounjaroTirzepatide36$47,494
JanuviaSitagliptin Phosphate47$44,273
OzempicSemaglutide30$33,465
FarxigaDapagliflozin Propanediol34$29,796
MyrbetriqMirabegron21$16,820
LinzessLinaclotide23$16,449
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,687
VascepaIcosapent Ethyl21$13,651
XareltoRivaroxaban13$11,824
Rosuvastatin Calcium229$4,466
SynthroidLevothyroxine Sodium36$3,892
Atorvastatin Calcium423$3,663
Varenicline Tartrate11$3,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$30$65,74185 claims
Lilly USA, LLCMounjaro$30$47,49436 claims
MerckJanuvia$125$44,27347 claims
Novo NordiskOzempic$32$33,46530 claims
AstraZenecaFarxiga$331$29,79634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →